Strategies to target PD-1/PD-L1 in the tumor microenvironment

Cellular Oncology · Published 2026-03-05 · DOI 10.1007/s13402-026-01181-x

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s13402-026-01181-x

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Predictive biomarkers for immunotherapy response in renal cell carcinoma: why have they failed? · Current Opinion in Urology · 2026 · Cites or is cited by this article
• Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs) · Cancer Immunology, Immunotherapy · 2025 · Cites or is cited by this article
• The ubiquitin-like protein FAT10 enhances the autophagy-mediated degradation of ZO-1 by stabilizing ATG3 to promote the lung metastasis of colon cancer · Cellular Oncology · 2026 · Same journal
• Reverse cardio-oncology: neuroendocrine axis activation and cardiovascular-disease-derived factors synergistically remodel the tumor microenvironment · Cellular Oncology · 2026 · Same journal
• TFAP2A enhances radioresistance of non-small cell lung cancer by transcriptionally activating BRCA1 · Cellular Oncology · 2026 · Same journal
• NAA50-mediated SLU7 stabilization promotes cisplatin resistance in bladder cancer via regulating MAP3K3 mRNA nuclear export and p38 MAPK activation · Cellular Oncology · 2026 · Same journal
• Lactylation shields S100A11 from degradation to promote gastric cancer metastasis · Cellular Oncology · 2026 · Same journal
• RNF114-PACSIN3 signaling axis promotes hepatocellular carcinoma progression by enhancing GLUT1 membrane retention and glucose uptake · Cellular Oncology · 2026 · Same journal
• Cis-3-hexen-1-ol suppresses bladder cancer progression by inducing mitophagy via the PCK2/AMPK/mTOR signaling pathway · Cellular Oncology · 2026 · Same journal
• Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis · Cellular Oncology · 2026 · Same journal